Acronym:
ANZUP 1603
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
Cancer Type | Prostate | ||
---|---|---|---|
Trial Type | Treatment | ||
Phase | Phase II | Tumour Stream | Prostate |
Age Range | 18 years and older | Cancer Stage | Metastatic or Widespread |
Sex | Male | Anticipated Start Date | |
Molecular Target | Anticipated End Date |
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Male |
Molecular Target | |
Tumour Stream | Prostate |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | |
Anticipated End Date |
Trial Summary
TheraP: A randomised phase II trial of 177 LuPSMA617 theranostic versus cabazitaxel in men with progressive metastatic castration resistant prostate cancer.
Lay Summary
Sponsor / Cooperative group
ANZUP
Participating Hospitals
Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
---|---|---|---|---|---|
Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Tan | Recruiting |